Reddy P L, Khanna S, Subhash M N, Channabasavanna S M, Rao B S
Department of Neurochemistry, National Institute of Mental Health and Neurosciences, Bangalore, India.
J Neural Transm Gen Sect. 1992;89(3):209-18. doi: 10.1007/BF01250673.
Erythrocyte membrane Na+,K(+)-ATPase activity was studied in drug naive patients with bipolar (BP) mania (n = 62) and unipolar (UP) depression (n = 60) and normal controls (n = 66). Compared to controls there was a significantly decreased Na+,K(+)-ATPase activity in UP depressives but no change in BP manics. However, lithium treatment caused a significant increase in Na+,K(+)-ATPase activity although there was no correlation between plasma lithium levels and enzyme activity. Plasma cortisol correlated inversely with Na+,K(+)-ATPase in UP depressives. Interestingly, the lithium responders [less than 50% Beck Rafaelson's Mania Rating Scale (BRMS) score] showed a significant increase in Na+,K(+)-ATPase activity compared to lithium nonresponders (greater than 50% BRMS score). These observations indicate that monitoring of Na+,K(+)-ATPase activity during lithium therapy is useful to predict a therapeutic response.
在未服用过药物的双相(BP)躁狂症患者(n = 62)、单相(UP)抑郁症患者(n = 60)和正常对照组(n = 66)中研究了红细胞膜钠钾ATP酶活性。与对照组相比,单相抑郁症患者的钠钾ATP酶活性显著降低,而双相躁狂症患者则无变化。然而,锂治疗导致钠钾ATP酶活性显著增加,尽管血浆锂水平与酶活性之间没有相关性。在单相抑郁症患者中,血浆皮质醇与钠钾ATP酶呈负相关。有趣的是,与锂治疗无反应者(贝克-拉法尔森躁狂量表(BRMS)评分大于50%)相比,锂治疗有反应者(BRMS评分小于50%)的钠钾ATP酶活性显著增加。这些观察结果表明,在锂治疗期间监测钠钾ATP酶活性有助于预测治疗反应。